You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The genome mapping firm had fallen out of compliance with respect to its loan agreement with Innovatus and will prepay $5 million toward the loan principal.
Of the 28 companies in the index, nine companies' share prices increased while the share values of 19 declined month over month.
The company's Q4 revenues exceeded Wall Street estimates and the clinical genetic testing and pharma services businesses outperformed expectations.
Of the 28 companies in the index, 16 companies' share prices increased while the share values of 12 declined month over month.
The company's Lyo-Ready 1-Step RT-qPCR mix is being used by diagnostic labs in China to develop screening assays for the virus.
Most diagnostics companies saw increases in share prices compared to last year, resulting in a significant jump in the 360Dx Index.
Gainers in the index outpaced the decliners 19 to nine, and the index outpaced the Dow Jones Industrial Average and Nasdaq Biotechnology Index but lagged the Nasdaq.
Of the 28 companies in the index, 21 companies' share prices increased while the share values of 7 declined month over month.
BD said TRC Capital Investment had made an unsolicited offer to BD shareholders to buy up to 500,000 shares of BD's stock at a price below the current market value.
The genetic testing firm is offering approximately 2.3 million shares at $11.25 per share and plans to use the funds for general corporate purposes.